

## Method

**Cite this article:** Tipton K *et al* (2021). Patient and caregiver engagement in the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System (HCHSS) process. *International Journal of Technology Assessment in Health Care* **37**, e13, 1–12. <https://doi.org/10.1017/S026646232000207X>

Received: 29 May 2020

Revised: 4 November 2020

Accepted: 11 November 2020


### Key words:

Stakeholder participation; Patient participation; Caregivers; Forecasting; Technology assessment; Biomedical

### Author for correspondence:

Kelley Tipton, E-mail: [ktiption@ecri.org](mailto:ktiption@ecri.org)

# Patient and caregiver engagement in the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System (HCHSS) process

Kelley Tipton , Jennifer De Lurio, Eileen Erinoff, Randy Hulshizer, Diane Robertson, Donna Beales, Damian Carlson, Christian Cuevas, Eloise DeHaan, Andrea Druga, Marcus Lynch, Misha Mehta, Maria Middleton, Brian Wilkinson and Karen Schoelles

ECRI, Center for Clinical Evidence and Guidelines, 5200 Butler Pike, Plymouth Meeting, PA 19462-1298, USA

## Abstract

**Objective.** The Patient-Centered Outcomes Research Institute (PCORI) horizon scanning system is an early warning system for healthcare interventions in development that could disrupt standard care. We report preliminary findings from the patient engagement process.

**Methods.** The system involves broadly scanning many resources to identify and monitor interventions up to 3 years before anticipated entry into U.S. health care. Topic profiles are written on included interventions with late-phase trial data and circulated with a structured review form for stakeholder comment to determine disruption potential. Stakeholders include patients and caregivers recruited from credible community sources. They view an orientation video, comment on topic profiles, and take a survey about their experience.

**Results.** As of March 2020, 312 monitored topics (some of which were archived) were derived from 3,500 information leads; 121 met the criteria for topic profile development and stakeholder comment. We invited fifty-four patients and caregivers to participate; thirty-nine reviewed at least one report. Their perspectives informed analyst nominations for fourteen topics in two 2019 High Potential Disruption Reports. Thirty-four patient stakeholders completed the user-experience survey. Most agreed (68 percent) or somewhat agreed (26 percent) that they were confident they could provide useful comments. Ninety-four percent would recommend others to participate.

**Conclusions.** The system has successfully engaged patients and caregivers, who contributed unique and important perspectives that informed the selection of topics deemed to have high potential to disrupt clinical care. Most participants would recommend others to participate in this process. More research is needed to inform optimal patient and caregiver stakeholder recruitment and engagement methods and reduce barriers to participation.

Horizon scanning is a systematic process that serves as an early warning system to inform decision makers about possible future opportunities and threats. Healthcare horizon scanning identifies novel technologies, innovations, or new uses of existing technologies (e.g., drugs, devices, procedures, diagnostics, and care processes) and trends with potential for future disruptions (i.e., positive or negative major changes). Disruptions could affect care access, delivery, setting, and costs; current diagnostic or treatment models; health disparities; healthcare infrastructure; patient health outcomes; and public health (1–3).

Healthcare horizon scanning has informed a variety of strategic planning activities. Public and private entities globally have long used information from formal or informal healthcare horizon scanning programs to inform commercial planning decisions, health services and clinical research prioritization, financial or operational planning, controlled diffusion of technologies, and information dissemination to policy makers, purchasers, and healthcare providers. Health insurance companies and government payers have used horizon scanning to inform coverage decisions. Also, some organizations, such as ECRI and EuroScan, have used it to inform decisions about health technology assessment (HTA) activities; indeed, horizon scanning marks the first step in evidence assessment (3).

From 2010 through 2015, the U.S. Agency for Healthcare Research and Quality (AHRQ) engaged ECRI to design, develop, and implement the first U.S. national Healthcare Horizon Scanning System (HHSS). It was primarily intended to inform comparative-effectiveness research investments made through AHRQ's *Effective Health Care Program* (4). The system's scope was broad—spanning therapeutics, diagnostics, and programs in fourteen AHRQ-defined priority areas (e.g., cancer and obesity) and a cross-cutting category (e.g., topics spanning

© The Author(s), 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

multiple conditions). The process obtained inputs from clinical and health systems stakeholders, but not from patient stakeholders, to inform decisions about which interventions had the highest potential to address unmet needs (3). The stakeholder recruitment process was similar to the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System (HCHSS) process (3). ECRI maintains a network of more than three hundred medical and scientific experts in more than twenty-five specialties.

In late 2018, PCORI engaged ECRI to implement and operate the PCORI HCHSS (<https://www.pcori.org/research-results/evidence-synthesis/pcori-health-care-horizon-scanning-system>) to better inform research investments (5). It builds on concepts and approaches from the AHRQ system. Although the PCORI HCHSS protocol is similar, the scope of the HCHSS is more focused, with one notable exception—healthcare trends. The PCORI HCHSS scans for and monitors interventions in five priority areas: Alzheimer’s disease and other dementias, cancer, cardiovascular disease, mental and behavioral health conditions, and rare diseases. Included interventions are anticipated to be clinically available in the United States outside the research environment within 3 years and are monitored up to 1 year after initial clinical availability (e.g., regulatory approval) (3). The system helps PCORI decide how to invest research funds. The public and research community can use the published information for research and decision-making.

The HCHSS also identifies high-level disruptive trends that occur across or within clinical areas that may create a paradigm shift in health care. PCORI does not limit the trends’ scope to the five priority areas (3). For example, the continued and rapid development of expert artificial intelligence systems in health care cuts across all clinical areas and increasingly transforms screening, diagnosis, and treatment (6).

A HCHSS hallmark is the inclusion of patient and caregiver perspectives in addition to clinical, health systems, and research perspectives. These added perspectives introduce more diverse thinking about an intervention’s disruption potential (3), such as how an intervention might affect health outcomes, adherence, or care processes. Furthermore, this stakeholder group supports PCORI’s initiatives to engage patients in research. This paper aims to describe our early experience and results from engaging patients and caregivers in the HCHSS process to help determine which new healthcare interventions have the highest disruption potential.

## Methods

### Horizon Scanning Process

The PCORI HCHSS process involves systematic, ongoing, scanning of hundreds of key information sources, from news aggregators like PRNewswire to clinical trial registries ([ClinicalTrials.gov](http://ClinicalTrials.gov)), trade publications, and peer-reviewed journals to identify topics (i.e., interventions) and trends likely to disrupt health care within the next 3 years. Analysts review potential topics and trends and, if interventions or trends meet the HCHSS protocol’s inclusion criteria (3), enter them into a database for nomination. At topic nomination meetings, analysts present each topic or trend to the HCHSS team. After brief discussion, the team uses a blind voting tool to include or exclude the topic or trend (based on protocol criteria). All included topics and trends are reported in a publicly available quarterly Status Report (7) that briefly describes each topic. Topics with late-phase clinical data are further

developed into more detailed reports—called topic profiles—compiled from the results of focused searches of published clinical data. For each topic profile, comments are obtained from five to nine stakeholders. The goal is to include at least one patient representative (e.g., patient or advocate) or caregiver in each stakeholder group for each topic profile.

The selected stakeholders are familiar with the topic profile’s clinical area, the disease or condition, or the health system generally so they can provide perspectives based on their knowledge and experience. The stakeholders engaged vary by topic profile. Each stakeholder reads the topic profile and completes a brief comment form, which elicits ratings on the intervention’s disruption potential on a scale of one (not disruptive) to four (highly disruptive). A brief written rationale is required to support each rating.


Twice yearly, PCORI HCHSS analysts review stakeholder ratings and comments received in the previous 15 months for each topic profile to nominate topics deemed to have the highest disruption potential for inclusion in a High Potential Disruption Report (HPDR) (3). See [Figure 1](#) for a process overview.

### Patient Stakeholder Recruitment Process

A Patient Engagement Specialist (PES) with a background in community outreach and program planning recruits individual patient and caregiver stakeholders from credible community sources, such as national advocacy organizations or healthcare consortiums (e.g., Consumers United for Evidence-based Healthcare). Patient stakeholders include people who have lived experience with a disease or condition, patient representatives, and patient advocates; we use the term “patients” to describe all three types. The PES searches the Internet for organizations relevant to the five priority areas and identifies a point of contact (e.g., outreach coordinator). Information about the identified organizations, such as the mission and contact detail, is tracked using Microsoft Office Excel 2016. The PES e-mails the contact, briefly describing the HCHSS and importance of patients and caregivers as commenters, and asks for support in identifying potential participants. The PES also extends an invitation to discuss the project further during a conference call. Our recruitment methods are informed by PCORI’s *Engagement Rubric* (8). The system protocol provides further details about our methods (3).

Once a patient or caregiver is identified, the Stakeholder Engagement Coordinator (SEC) e-mails a welcome message describing the HCHSS and commenter responsibilities and requests details about the stakeholder’s lived experience and role. Next, the PES e-mails the stakeholder a 10-minute audiovisual presentation describing project goals, the importance of engaging patient stakeholders in the process, key terminology, and how comments are used. A sample report and comment form are also provided.

When a topic profile suiting their experience is ready for review, stakeholders receive an e-mail query from the SEC that they may accept or decline. Acceptance automatically sends the five- to seven-page topic profile and comment form link to the stakeholders’ inbox. They have 5 business days to submit their review electronically. Stakeholders are asked to disclose potential conflicts of interest. Conflicts do not limit participation. Instead, we seek to balance their views with inputs from other neutral parties, including ECRI’s own experts. The SEC tracks and logs comment form submissions into a database (where they are stored for analyst review), sends reminders to complete assigned reviews, and may extend deadlines as needed. External stakeholders



**Figure 1.** Presents an overview of the ongoing HCHSS process. Step one involves broad scanning by information specialists to identify leads for potential topics. In step two, analysts review leads to identify topics that meet disruption criteria. In step three, topics are nominated, discussed, and voted on by the team for inclusion. Step four involves topic development followed by step five when topics with late-phase data are sent for stakeholder comment. The last step in the process, step six, is the development of the HPDR.

(non-ECRI employees) complete a U.S. Internal Revenue Service W-9 tax form to receive an honorarium of \$250 for each report reviewed with comment form completed. The SEC who manages the review process is a medical copyeditor who draws on experience obtaining reviews, a typical copyeditor task, from the AHRQ HHSS experience.

#### How Stakeholder Comments Are Used

The stakeholders' comments and ratings for each topic profile, including those from patients and caregivers, inform analysts about which topics to recommend as having high disruptive potential (3). Throughout this process, patients and caregivers have provided unique perspectives (Table 1).

Analysts review stakeholders' numeric ratings and comments for each topic profile and note whether strong consensus or variation exists, whether the disruption potential crosses multiple parameters (e.g., patient outcomes and delivery of care), and the overall projected disruption magnitude.

Analysts may identify topics as potentially highly disruptive when similar substantive comments and scores are received across many parameters or by most or all commenters. Conversely, comments and scores may indicate a substantial anticipated effect, but only in one or a small number of parameters or by a small number of stakeholders. Although no particular stakeholder's comments receive more weight at the outset, analysts may weigh more heavily comments from those who demonstrate considerable experience and knowledge in a clinical area. For example, comments from stakeholders in direct contact with patients (e.g., clinicians) or directly affected by the disease or condition (e.g., caregivers) may be deemed more pertinent.

#### Patient Stakeholder Experience Survey

ECRI collects and evaluates patients' and caregivers' views of this process by administering a participation experience survey. Survey administration began on 4 June 2019 using Checkbox survey software. The survey includes seven questions with a four-point Likert-type scale (agree [four points], somewhat agree, somewhat disagree, and disagree [one point]). We chose a four-point scale for

similarity to the scale used on the topic profile rating and comment form and to avoid respondents' tendency to choose the mid point. Question seven includes a free-text box for respondents to explain their response. Question eight allows respondents to enter additional comments in a free-text box. Respondents are also asked which stakeholder group(s) they represent (e.g., patient and caregiver).

After a participant's first review is received, the survey is e-mailed to the participant (Supplementary File 1). One week later, a reminder e-mail is sent if a completed survey has not been received. Checkbox captures the survey results. The PES downloads them into Microsoft Excel and reviews them, and then a senior member of the project leadership team reviews them. Our team then writes an internal report to help inform and improve our engagement efforts.

## Results

### Horizon Scanning Operations and Patient Stakeholder Recruitment and Participation Data

From 7 December 2018 through 13 March 2020, analysts reviewed about 3,500 information leads and identified about 520 potential topics across the five priority areas. Ninety-two high-level trends were also identified across all areas of health care. After applying the HCHSS inclusion criteria, nomination, and voting process, 312 topics were selected and monitored; some were archived for various reasons (e.g., the intervention failed to meet clinical trial end points). Of the 312 topics, 121 topic profiles were developed, of which 105 were sent for stakeholder comment and 16 were archived. Using the HCHSS inclusion criteria and nomination process, thirty-two trends were selected, actively monitored, and sent for stakeholder comment. No trends were archived as of March 2020.

From 1 March 2019 through 13 March 2020, the PES contacted 122 organizations pertaining to the five HCHSS priority areas to request support identifying patient stakeholders. Outreach efforts led to fourteen conference calls with national advocacy organizations, international patient discussion platforms, and individual patient stakeholders. To date, fifty-four patient stakeholders have been invited to participate in the

**Table 1.** Effect of patient stakeholder comments on analyst inclusion recommendations for the HPDR

Topic	Stakeholder type	Comment summary	Analyst assessment of comments	Effect on analyst inclusion recommendation for report
Alzheimer's disease topic				
Periodic plasma exchange (Alzheimer's Management by Albumin Replacement) to treat Alzheimer's disease	Caregiver	<ul style="list-style-type: none"> <li>• Treatment could differ based on patients' access to an infusion center. Access might be an issue in rural areas.</li> <li>• Insurance coverage could impact the overall cost and availability of this treatment protocol.</li> <li>• Uptake might depend on patients' primary care physician, neurologist, and caregiver.</li> </ul>	Three caregivers' responses agreed that the lack of insurance coverage would likely affect disparities as well as healthcare costs for patients and caregivers. Their perspectives on anticipated side effects and manufacturers' claims were very useful.	(November 2019 report) Caregivers highlighted concerns about treatment cost, insurance coverage, and accessibility in rural areas. Caregivers noted that the study data seem promising but raised some concerns about generalizability and anticipated side effects of this treatment.
Cancer topics				
Atezolizumab (Tecentriq) first-line treatment for locally advanced or metastatic triple-negative breast cancer	Caregiver and patient representative	<ul style="list-style-type: none"> <li>• A longer progression-free survival will give patients and family members some time before deciding upon an alternative treatment once the disease progresses.</li> <li>• This drug treatment might improve the quality of life for patients and caregivers if the confirmatory trials show a better side-effect profile than current treatment options.</li> <li>• It might increase disparities because of the lack of adequate transportation to a treatment site for those commonly diagnosed with TNBC (minorities and underserved communities).</li> <li>• Treatment cost is prohibitive even for those with insurance (due to high copayments) and unattainable for those without private health insurance or federal assistance.</li> </ul>	A caregiver and two patient representatives agreed that this drug might provide hope for patients with this aggressive breast cancer, given the poor prognosis. The patients raised concerns about the high cost of the treatment and access by those without insurance coverage.	(November 2019 report) Caregiver and patient perspectives were contingent on results from confirmatory trials, and they thought this treatment might provide clinical benefit while reducing the risk for adverse events. Patient representatives provided valuable insights into the lack of patient education available to make an informed decision about their treatment plan, along with other concerns including treatment cost and access issues.
Lifileucel (LN-144) second-line treatment for locally advanced or metastatic melanoma	Patient advocate	<ul style="list-style-type: none"> <li>• Patients with late-stage melanoma have limited treatment options and are very interested in a new intervention that can improve survival.</li> <li>• Patients have concerns about how this new cell therapy might affect their case management and how expensive it is likely to be.</li> <li>• Because this intervention is a personalized treatment that requires time for its preparation, patients are concerned that it would take longer to receive treatment than with the standard of care.</li> <li>• Patients seem open to try a new approach to treat a disease with limited treatment options and believe that clinicians would be also willing to try offering this intervention. Patients would like to have more information about costs, risks of hospitalization and infection, and barriers that will limit its access to patients.</li> </ul>	The advocate gave comments that were clear and helped assess the intervention's potential for disruption.	(November 2019 report) The advocate made the analyst aware that patients with late-stage melanoma have limited options and that this intervention offers a novel treatment approach. The patient advocate also gave an insight into what patients expect from a new therapy for melanoma and whether they can afford it. They want an effective treatment, but also want to know whether it is associated with additional risks.

*(Continued)*

Table 1. (Continued.)

Topic	Stakeholder type	Comment summary	Analyst assessment of comments	Effect on analyst inclusion recommendation for report
Pembrolizumab (Keytruda) first-line treatment for locally advanced or metastatic recurrent head and neck squamous cell carcinoma	Patient	<ul style="list-style-type: none"> <li>• Patients are very interested in a new drug intervention that can improve survival, but they are also concerned about treatment-related adverse events because they have great influence on the quality of life.</li> <li>• Patients are concerned that new interventions that are very expensive will be accessible only to those who can afford them, which will be limited to a small group of patients, unless insurance companies are willing to absorb most of the cost.</li> <li>• Patients are unconcerned about how a new intervention will affect case management. If it improves health-related outcomes without increasing adverse events, patients are open to changes in management.</li> <li>• Overall, patients are most interested in both short- and long-term treatment-related adverse events and the financial implications of receiving a new therapy.</li> </ul>	The patient was very knowledgeable and focused not only on efficacy, but also on adverse events that might reduce the quality of life. Comments were clear and very helpful for assessing pembrolizumab's disruption potential.	(November 2019 report) The patient was very knowledgeable about treatments for HNSCC. The comments made analysts realize that patients are focused not only on the efficacy of new interventions but also on adverse events, because they affect the quality of life. One big concern expressed is the accessibility of pembrolizumab because of its very high price. The patient indicated that many patients will be unable to afford treatment unless third-party payers are willing to absorb most of the cost.
Cardiovascular disease topics				
Cardiac contractility modulation (Optimizer) to treat moderate-to-severe heart failure	Patient	<ul style="list-style-type: none"> <li>• Optimizer device offers a treatment option for patients whose condition continues to deteriorate.</li> <li>• More research is needed in female and ethnic groups.</li> <li>• Increased need exists for more staff to deliver and monitor care.</li> <li>• Treatment gap exists between current medical therapy and highly invasive options.</li> </ul>	The patient expressed more positive comments than clinicians or researchers and presented different points to consider.	(May 2019 report) The patient raised several points to consider. The patient reviewer seemed very informed about the conduct and design of clinical trials. Giving patients more responsibility for their care delivery was viewed very positively. The patient raised questions about data generalizability and application to specific subsets of the heart failure population who might benefit most.
Organ Care System to preserve donor hearts in near-physiologic state for transplantation to treat end-stage heart failure	Caregiver	<ul style="list-style-type: none"> <li>• Learning curve for this device would mostly affect clinical personnel and current transplant procedures.</li> <li>• Increasing donor organ availability might moderately reduce disparities.</li> <li>• Conversely, disparities could increase at centers that lack this organ-preservation technology.</li> <li>• Change in organ preservation could expand donor organ supply and accessibility.</li> </ul>	The caregiver acknowledged how this more technological development could improve patient care by increasing the supply of donor hearts. The reviewer noted that most transplant surgical techniques would likely remain similar.	(November 2019 report) The caregiver focused on this technology's potential to increase patient access to heart transplantation as an important factor in either reducing disparities or increasing them if the system is not adopted or is unavailable.
Paradise Renal Denervation System to treat medically refractory hypertension	Patient	<ul style="list-style-type: none"> <li>• More data are needed to define the long-term safety of this device and protocol for ablating the renal nerves.</li> <li>• Physicians' treatment recommendations could differ greatly for 25-year olds versus 75-year olds.</li> <li>• Insurance coverage could affect availability and patient acceptance.</li> <li>• Drug companies could push back against losing a large patient</li> </ul>	The patient provided a good and detailed perspective on the current data gaps and the lack of cost estimates. Good points on disparity risk regarding different patient ages and geographic access.	(November 2019 report) The patient noted that blood pressure changes are clinically important but not a practical patient-centered outcome. Useful future point from a patient perspective would capture whether this procedure could effectively reduce medication use, thus improving the quality of life. The patient helpfully noted that more patient subgroup clarification and

(Continued)

**Table 1.** (Continued.)

Topic	Stakeholder type	Comment summary	Analyst assessment of comments	Effect on analyst inclusion recommendation for report
		<p>population taking blood pressure drugs lifelong.</p> <ul style="list-style-type: none"> <li>Older patients might not have access because of procedural risks.</li> </ul>		outcomes data are needed to define safety and efficacy.
Rare disease topics				
Casimersen to treat Duchenne muscular dystrophy	Caregiver	<ul style="list-style-type: none"> <li>Increasing dystrophin production is likely to improve muscle function and patient quality of life.</li> <li>Slowing disease progression might delay serious health complications, delay and reduce healthcare resource use, and might allow patients to maintain insurance coverage for a longer period.</li> <li>Weekly infusion with this drug might be inconvenient and might increase disparities in treatment and care.</li> <li>This treatment might be too costly, especially if limited data lead to limited or no insurance coverage.</li> <li>If patients can afford the drug, it might reduce healthcare costs associated with this very expensive disease.</li> </ul>	Two caregivers gave very thorough responses that were helpful in understanding their differing perspectives when taken into consideration along with numeric ratings. These responses echoed comments from reviewers of different backgrounds.	(November 2019 report) Caregivers thought that a drug that demonstrates potential to increase dystrophin production might significantly delay progression of this disease, which has significant and devastating effects on patient health outcomes, the quality of life, caregiver burden, and healthcare costs. Furthermore, caregivers communicated that the drug might significantly disrupt the ease of access to treatment and disparities.
Crizanlizumab-tmca to prevent vaso-occlusive crises from sickle cell disease	Caregiver	<ul style="list-style-type: none"> <li>The drug crizanlizumab-tmca might substantially improve health outcomes by reducing the number and duration of crises for patients with SCD who are unable to use hydroxyurea or who have the HbS/S genotype.</li> <li>Health insurance coverage is a major concern; many patients are of low socioeconomic status.</li> <li>Medicaid, state insurance programs, and copayments will be important for acceptance and uptake of treatment.</li> <li>There is fear that even if treatment is effective, health disparities might lead to slow adoption.</li> </ul>	The caregiver confirmed the disruptive potential stated by other commenters and informed some of the realities of life for patients with SCD in light of the limited treatment options available.	(May 2019 report) The caregiver provided well-articulated concerns about cost and insurance coverage issues for SCD and SCD-related disorders. Detailed comments gave the review more weight than short, generalized (or generic) comments provided by other reviewers who were not patients or caregivers.
Fenfluramine hydrochloride low-dose (Fintepla) to treat Dravet syndrome	Caregiver and patient advocate	<ul style="list-style-type: none"> <li>Reducing seizure activity improves the quality of life for both patients and caregivers.</li> <li>The side effects of this drug are similar to those of other antiepileptic drugs and to the symptoms of Dravet syndrome.</li> <li>A drug that reduces seizure duration is important to this patient population.</li> <li>This intervention might shift the treatment setting if it leads to fewer emergency department visits and inpatient stays for seizures.</li> <li>This intervention does not deviate significantly from the current paradigm of care and might require concomitant use with other antiepileptic drugs.</li> </ul>	The caregiver and the patient advocate comments informed the analyst about what is most important to patients and caregivers of Dravet syndrome when it comes to seizure control.	(November 2019 report) Although this drug might not significantly affect the paradigm of care, its potential to reduce seizure frequency (and if it might reduce seizure duration) is likely to significantly impact health outcomes and the quality of life for both patients and caregivers.

(Continued)

Table 1. (Continued.)

Topic	Stakeholder type	Comment summary	Analyst assessment of comments	Effect on analyst inclusion recommendation for report
Galcanezumab-gnlm (Emgality) to treat episodic cluster headache	Patient	<ul style="list-style-type: none"> <li>Reducing cluster headache symptoms might help reduce the negative psychological impact of the condition, improving the quality of life.</li> <li>The home setting for taking this drug might significantly help patients who otherwise find it difficult to leave the home for treatment while symptomatic.</li> <li>Although the drug is likely to be expensive, if it is highly efficacious it might drastically reduce other costs such as emergency department visits and other expensive medication injections.</li> <li>Patients are encouraged by drug development to treat cluster headaches, because they are in need of additional, effective treatments.</li> </ul>	Two patients' comments informed the analyst about the areas that are most important to them for the quality of life and areas for potential disruption. The patients also provided perspectives of the cluster headache community as a whole, because these patients also had experience with patient advocacy groups.	(November 2019 report) It was apparent how important drug innovations are in this population, because cluster headaches are debilitating physically and psychologically. The comments helped explain the significant impact this intervention might have on patient quality of life, especially given the outpatient care setting and improvement in symptoms.
Idebenone to treat Duchenne muscular dystrophy	Caregiver	<ul style="list-style-type: none"> <li>Current standard of care (corticosteroids) carries significant side effects and can be used for only a short time.</li> <li>Many patients have disrupted eating schedules due to difficulties in chewing and swallowing, so it might be difficult to adhere to this drug's meal-related treatment regimen.</li> <li>Treatment might indirectly reduce the costs of side effects and secondary illnesses caused by corticosteroid use.</li> <li>Diffusion of treatment might be limited if idebenone's cost is significantly higher than that of corticosteroids.</li> </ul>	The caregiver echoed the sentiments of other commenters about the intervention's overall potential to cause disruption. The comments were very useful when determining whether the intervention has high potential to improve patient outcomes and disrupt other facets of health care.	(May 2019 report) The caregiver's specific details were enlightening about how this drug's potential shortcomings could affect patient and physician acceptance. The caregiver was concerned that the small patient sample in trials might have not identified all possible side effects of this therapy. Details about the quality of life with existing treatments were useful background information.
LentiGlobin to treat transfusion-dependent $\beta$ -thalassemia	Caregiver and patient representative	<ul style="list-style-type: none"> <li>Patients with TDT have limited treatment options, including blood transfusions and HSCT that requires a matched donor.</li> <li>Most patients with TDT are treated with blood transfusions, which prevent patients from living independently and substantially reduce the quality of life and daily activities because of adverse events (e.g., iron overload, requiring chelation therapy), office visits, and costs of copayments.</li> <li>LentiGlobin presents a drug treatment option for patients without a matched HSCT donor and might substantially improve daily living, even if it only reduces transfusion frequency. It also presents the potential to transition treatment from tertiary to prophylactic management.</li> <li>Typically, patients with TDT do not have private insurance.</li> <li>Concerns exist regarding the exclusion of patients aged 50 years or older in clinical trials.</li> </ul>	The caregiver's and patient representative's comments were very informative about the substantial burden in the quality of life, health outcomes, and cost that transfusion dependence places on patients and caregivers. Treatments for TDT are greatly welcomed by the patient community.	(November 2019 report) The caregiver and patient representative confirmed positive sentiments held by other stakeholders that LentiGlobin might improve health outcomes and the quality of life in patients with TDT by reducing transfusion dependence. The caregiver and patient representative provided a unique insight into the daily quality of life and cost burden for patients with TDT not provided by other stakeholders.

(Continued)

**Table 1.** (Continued.)

Topic	Stakeholder type	Comment summary	Analyst assessment of comments	Effect on analyst inclusion recommendation for report
Luspatercept-aamt (Reblozyl) to treat transfusion-dependent $\beta$ -thalassemia	Caregiver	<ul style="list-style-type: none"> <li>• Transfusion dependence has physical, psychological, social, and logistical quality-of-life impacts.</li> <li>• Patients are very interested in incremental improvements in quality of life that are realistically achievable, compared with the ultimate goal of a cure far off in the future.</li> <li>• Patients with TDT would really welcome a comparably effective therapy that reduces clinic visits, compared with transfusions and iron chelation, and in a treatment that could improve quality of life and work productivity.</li> <li>• Outstanding questions of how this new drug treatment's costs will compare to regular transfusions need to be answered.</li> </ul>	The caregiver's very thorough responses helped in the understanding of perspectives and correlated well with the given numeric ratings. Details were among the most helpful of all reviews on this topic.	(November 2019 report) The caregiver provided an insight into patients' perspectives about what they realistically want in new treatments, beyond the ultimate goal of a distant cure that many patients might not reach. Detailed comments on the effect of the quality of life of existing transfusion therapy were useful background information.

*Note:* This table shows patient stakeholder perspectives with their impact on inclusion recommendations for the May 2019 and November 2019 editions of the HPDR. The five column headings from left to right are: topic, stakeholder type, comment summary, analyst assessment of comments, and effect on analyst inclusion recommendation for report. The topics are arranged vertically by clinical condition with the following headings: Alzheimer's disease topic (row two), cancer topics (row four), cardiovascular disease topics (row eight), and rare disease topics (row twelve).

Hbs/S, hemoglobin S; HNSCC, head and neck squamous cell carcinoma; HSCT, hematopoietic stem cell transplantation; SCD, sickle cell disease; TDT, transfusion-dependent  $\beta$ -thalassemia; TNBC, triple-negative breast cancer.

HCHSS. As of 13 March 2020, thirty-nine patients and caregivers had completed eighty-three reviews. We were unable to identify patient stakeholders with experience related to the remaining twenty-two topic profiles. Participants in our database who have yet to complete a review will be contacted when a report in their area of experience is available. [Table 2](#) shows the number of completed patient stakeholder reviews by the clinical area.

### *Impact of Patient Stakeholder Comments on the HPDR*

Patient and caregiver stakeholder perspectives inform analysts' inclusion recommendations for the HPDR. Patient and caregiver comments either confirm other stakeholder perspectives or provide new perspectives, as seen in three topics in the May 2019 HPDR and eleven in the November 2019 HPDR (9;10).

For example, one topic profile in the May 2019 HPDR was about a drug intervention, called idebenone, to treat Duchenne muscular dystrophy (9). Six stakeholders provided comments, including a caregiver. The analyst covering this therapeutic area stated that the caregiver's detailed comments about ways this drug's potential shortcomings could affect patient and physician acceptance were enlightening. The caregiver noted that the small number of patients in trials might have prevented discovering all possible side effects of the therapy. This stakeholder also discussed the quality of life with existing treatments, which was a useful background for the analyst. Overall, the analyst reported that this perspective highly influenced his inclusion recommendation for the HPDR. [Table 1](#) shows this result and additional examples of impact of patient stakeholder input on the HPDR.

### *Patient Stakeholder Experience Survey*

Of the fifty-four invited patient stakeholders, thirty-nine commented on at least one report and had been surveyed as of

March 2020. Of those surveyed about their experience, 92 percent (thirty-six patient stakeholders) responded. Two submissions were excluded from the interim results because one stakeholder submitted a blank survey and another indicated never receiving a report to review. Of the remaining thirty-four, respondents represented various groups: thirteen were patients, four were caregivers, three were patient advocates, and fourteen held dual roles, such as a patient and caregiver or a patient and advocate.

The most frequent responses were "agree" or "somewhat agree" ([Table 3](#)). Responses to the following four questions are of particular interest because they will help us evaluate how we prepare patient stakeholders for the review process: question one (felt prepared to review the report and complete the comment form), two (found the report easy to understand), five (was confident about the ability to provide useful comments), and seven (would recommend other patient stakeholders to participate). Also, responses helped identify the need to modify report content for this stakeholder group, such as increasing plain language use and using technical terms only when necessary (11;12).

A total of 85 percent felt prepared to review the report and complete the comment form (question one), and 65 percent agreed and 26 percent somewhat agreed that the report was easy to understand (question two). A total of 68 percent agreed and 26 percent somewhat agreed that they were confident in their ability to provide useful comments (question five). Almost all (i.e., 94 percent) would recommend other patient stakeholders to participate as reviewers (question seven).

Of the respondents, 3–9 percent somewhat disagreed with questions two, three, four, and five because they found the report or comment form difficult to understand, the comment form difficult to use, or lacked confidence in their ability to provide useful comments. In responses to questions seven (recommend others to participate) and eight (any additional comments), the participants



**Table 2.** Patient and caregiver stakeholder reviews by disease or condition

Disease or condition	Reviews	Disease or condition	Reviews
<b>Alzheimer's disease and other dementias, total</b>	<b>5</b>	<b>Mental and behavioral health, total</b>	<b>5</b>
Alzheimer's disease	3	Attention-deficit/hyperactivity disorder	2
Dementia-related psychosis	2	Anxiety	1
<b>Cancer, total</b>	<b>22</b>	Bipolar disorder	1
Breast	11	Postpartum depression	1
Myeloma	3	<b>Rare diseases, total</b>	<b>47</b>
Endometrial	1	Duchenne muscular dystrophy	17
Graft-versus-host disease	1	Sickle cell disease	8
Head and neck	1	$\beta$ -thalassemia	4
Leukemia	1	Neuromyelitis optica	4
Lung	1	Cluster headache	3
Lymphoma	1	Dravet syndrome	2
Melanoma	1	Lambert-Eaton myasthenic syndrome	2
Pancreatic	1	Multiple sclerosis	2
<b>Cardiovascular conditions, total</b>	<b>4</b>	Narcolepsy	2
Heart failure	3	Behçet's disease	1
Hypertension	1	Cystic fibrosis	1
		Spinal muscular atrophy	1
<b>Total</b>			<b>83</b>

Note: From the first review received 18 April 2019 through 13 March 2020.

This table shows the topics representing the five priority areas reviewed by patient stakeholders. The first and third columns show the specific diseases or conditions. The second and final columns show the number of reviews for each clinical disease or condition. As of March 2020, patient stakeholders had completed eighty-three reviews in the PCORI HCHSS.

**Table 3.** Results of patient stakeholder experience survey

Survey question	Number of responses	% Agree (n/N)	% Somewhat agree (n/N)	% Somewhat disagree (n/N)	% Disagree (n/N)	Mean response <sup>a</sup>
1. I was prepared to review the report and complete the comment form.	33	85 (28/33)	15 (5/33)	0 (0/33)	0 (0/33)	3.8
2. The report was easy to understand.	34	65 (22/34)	26 (9/34)	9 (3/34)	0 (0/34)	3.6
3. The comment form was easy to understand.	34	68 (23/34)	29 (10/34)	3 (1/34)	0 (0/34)	3.6
4. The comment form was easy to use.	34	82 (28/34)	15 (5/34)	3 (1/34)	0 (0/34)	3.8
5. I was confident in my ability to provide useful comments for the PCORI HCHSS.	34	68 (23/34)	26 (9/34)	6 (2/34)	0 (0/34)	3.6
6. I am satisfied with my experience as a reviewer for the PCORI HCHSS.	34	88 (30/34)	12 (4/34)	0 (0/34)	0 (0/34)	3.9
7. I would recommend that other patient stakeholders participate as reviewers for the PCORI HCHSS.	33	94 (31/33)	6 (2/33)	0 (0/33)	0 (0/33)	3.9

Note: This table shows the results from the patient stakeholder experience survey, which is a seven-question Likert-type survey. The seven column headings from left to right are: survey question, number of responses, percentage agree, percentage somewhat agree, percentage somewhat disagree, percentage disagree, and mean response.

Thirty-nine surveys were sent and thirty-six responses were received from 4 June 2019 through 13 March 2020. One recipient submitted a blank survey and one indicated never receiving a report to review. These responses have been excluded from the results reported here.

n, number of survey responses; N, number of respondents surveyed; PCORI HCHSS, Patient-Centered Outcomes Research Institute Health Care Horizon Scanning System.

<sup>a</sup>Response option ratings: agree = 4, somewhat agree = 3, somewhat disagree = 2, disagree = 1.

expressed difficulty in understanding the terminology used in the report and the comment form and desired more preparation before completing a review.

A total of 71 percent of respondents provided an explanation for why they would or would not recommend that other patient stakeholders participate as commenters in the HCHSS. One

patient said, “This is a great opportunity for patients to advocate for themselves, as well as others. I would recommend this to anyone who has been touched by a disease.” Themes that emerged from comments recommending participation were as follows:

- A minimal time commitment (8 percent)
- A user-friendly system and process (13 percent)
- An opportunity to advocate and offer immediate feedback, be involved in research, and learn about new treatments (54 percent)
- An important way to capture patient stakeholder perspectives (29 percent)

Reasons respondents would not recommend others to participate included the following:

- Difficulty in understanding the terminology used in the report or the comment form (13 percent)
- Discomfort when reviewing the report and completing the comment form (4 percent)
- Need for more preparation or training before participation (8 percent)
- Need to identify the “right” patient stakeholders to participate, such as those with experience providing reviews (13 percent)

Lastly, we asked respondents for any additional comments about their experience as reviewers. One patient expressed that “this process seeks information in a way that frames the patient in the broader system and assesses the patient and provider in their lived environment.” Of the 44 percent who responded, comments included the following:

- A rewarding process for patients and caregivers (13 percent)
- An appreciation of the opportunity to participate as a commenter (60 percent)
- A request for more training about the patient role in the HCHSS (7 percent)
- Unfamiliarity with some of the terminologies (13 percent)
- A desire for education on interpreting statistics in drug studies (7 percent)
- A request for more details or background on the disease of interest (13 percent)

## Discussion

Patient and public involvement describes a broad range of efforts to include these stakeholders in processes that guide health system decision-making (13). HTA organizations have used various frameworks to incorporate patient and public perspectives that enhance the transparency of decision-making processes (14). The approach often depends on the HTA organization or project type. For example, the U.K. National Institute for Health and Care Excellence (NICE) promotes fairness and patient inclusion in decisions related to their health and well-being (15). The Canadian Agency for Drugs and Technologies in Health (CADTH) involves patients on working groups and committees at several levels in the assessment process for medications and medical devices (15). In January 2020, the U.K. National Institute for Health Research launched the Centre for Engagement and Dissemination to make research representative, relevant, and ready to use by stakeholders (16). The U.S.-based Institute for Clinical and Economic Review (ICER), focusing on

cost-effectiveness studies for healthcare interventions, mainly pharmaceuticals, updated its *Value Assessment Framework* in January 2020 detailing procedures for including patient experiences and values in ICER evidence reviews (17).

Although the goal of patient engagement is similar for horizon scanning and HTA, the timing of engagement varies. Horizon scanning is the first step in the traditional HTA timeline and a point at which clinical data, used to consider the potential value of interventions, are typically scant. Our report is one of the first to describe and evaluate a process for including patient stakeholder perspectives at this early stage. Our results illustrate how patient perspectives influenced decisions to determine the health-care disruption potential of topics considered for the PCORI HCHSS HPDR and what patient stakeholders thought of the review process.

In contrast, the CADTH Common Drug Review program seeks patient input to frame assessments used to develop reimbursement recommendations (18). Similarly, the NICE invites patient stakeholders to submit a written statement to be considered along with clinical and economic data when drafting guidance documents (19).

Stakeholder perspectives have become a cornerstone of the HCHSS process. Even before this work, ECRI created and maintained relationships with stakeholder reviewers across the health-care provider and payer continuum and included patient representatives, caregivers, and advocates in work on patient reference guides (3;20;21). Expanding our HCHSS stakeholder database to include patients, caregivers, and advocates has enhanced analysts’ insight into real-life implications of interventions in development and issues of importance to these stakeholders (e.g., patient-oriented outcomes and costs). We, like Simpson, Cook, and Miles (22), have found that in an Early Awareness and Alert system, patients add valuable and unique perspectives on the quality of life, acceptability, and ease of use regarding a technology’s potential impact for end users.

An important aspect of stakeholder engagement for patients is to provide a meaningful engagement opportunity in which they believe their input is useful and has an impact on the project. One way to assess this in the HCHSS is to survey patient and caregiver stakeholders and use the responses to revise and improve all aspects of engagement. Although the current sample size is small, stakeholders’ most frequently selected responses suggest they believe that their engagement was meaningful. According to HCHSS analysts, patient stakeholder perspectives have informed HPDR topic inclusion decisions by providing inputs that might not otherwise be captured, such as their lived experience with a condition.

Our survey results also indicate several ways to improve the experience by revising our preparation activities to offer more training before the review experience and using more plain language in writing topic profiles.

We also recognize that using a four-point Likert-type survey scale sometimes requires responses that might not reflect a respondent’s true opinion. A five-point scale typically provides a “neither agree nor disagree” response option, which might better align with some respondents’ level of agreement with particular questions. However, the five-point scale has drawbacks including potential overuse of the middle category if one is unsure or ambivalent about the question—the mid point can be less informative (23;24).

Another challenge is using clinically and scientifically accurate language that is also understandable to patients and caregivers.

Plain language use is essential to engaging patient stakeholders. Studies continue to show that jargon-filled writing alienates readers, even when definitions are provided (25). Supplemental File 2 compares the language from the comment form used to gather clinical, research, and health system stakeholder comments and the form used to gather patient stakeholder comments. Both groups are highly experienced, but in different ways. As such, we sought to make the plain language questions more direct and concise while maintaining a high engagement.

Additionally, preparing patient stakeholders for their tasks, providing ongoing support and feedback when necessary, and sending updates about the end product (e.g., HPDR publication) enhance engagement for all concerned. Sometimes stakeholders ask whether their first review met expectations, and the SEC works with analysts to provide individual feedback.

After the biannual HPDR is published, the PES e-mails patient stakeholders with the link to the publication to show participants how their comments were used and provides suggestions for sharing the report on social media platforms. Abelson et al. (13) note that an enabler to meaningful public and patient involvement includes appropriate supports for patient and public committee members. These authors (13) also found that key organizational challenges to public and patient involvement include time, financial resources, and expertise to support high-quality involvement. Simpson, Cook, and Miles (22) recommend embedding patient and public engagement into early awareness and alert systems and allocating resources for the activities.

From the beginning, the HCHSS project allocated such resources (i.e., PES and SEC roles) to recruit, prepare, and communicate with stakeholders. Recruiting enough patient stakeholders with experience in specific therapeutic areas, particularly for rare disease conditions, has been the biggest challenge. Abelson et al. (13) faced similar challenges. HCHSS outreach efforts to more than 100 national advocacy organizations and consortiums resulted in a response rate of about 11 percent, which we would like to improve. Our current participants sometimes, but infrequently, refer other patient stakeholders. In light of these recruitment challenges, the generalizability of patient stakeholder comments is limited for a given topic profile.

We are establishing a presence on social media platforms. Our posts include text and graphics to increase visibility and attract potential stakeholders. Using the top social media platforms Twitter, Facebook, and LinkedIn, we are offering content of interest to our target population, such as our February 2020 kickoff topic, which focused on Rare Disease Day. The posts are meant to be informational, serve as a recruitment tool, and provide a link to the HPDR. The recruitment content links to a brief survey to determine whether a stakeholder is interested in participating as a reviewer. We also plan to “scrape” select social media platforms for specific topic areas (e.g., new drugs) that meet HCHSS inclusion criteria and use sentiment analysis tools to examine the content for potential trends. Anecdotally, major end users of the HCHSS are PCORI, payers, and international government agencies; social media and web analytics will advance our engagement with the patient end user, too.

## Conclusions

Understanding which treatments have the highest potential for disruption relies on stakeholder input to drive topic selection for each HPDR. Patient stakeholder perspectives have enhanced the selection process; most patient stakeholders would

recommend others to participate. Our experience presents an upstream approach to capture patient stakeholder voices and offers methods to assess the impact of their perspectives and protocols to evaluate the meaningfulness of this type of engagement. Future research is needed to inform best practices for patient stakeholder recruitment, to identify and assess meaningful engagement opportunities, and to improve preparation activities to reduce barriers to engagement for this stakeholder group.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S026646232000207X>.

**Acknowledgments.** The authors gratefully acknowledge the following ECRI staff for their contributions to this project: Rosemary Walker, MLIS; Jonathan Treadwell, PhD; Katherine Donahue; Helen Dunn; and Cassia Hulshizer. William Lawrence, MD, MS, and Gowri Raman, MBBS, MS, representatives from PCORI, served as contracting officers and technical representatives and provided inputs during the implementation of the HCHSS. PCORI stipulates the broad clinical areas that the HCHSS covers. PCORI does not directly participate in the day-to-day horizon scanning process, assess leads, or decide which topics to monitor or include in the HPDR. PCORI does not provide opinions regarding the potential impact of interventions.

**Funding.** The PCORI HCHSS is operated by ECRI under contract to PCORI. All authors were funded by PCORI (Contract No. MSA-HORIZONSCAN-ECRI-ENG-2018.7.12).

**Disclaimer.** All statements in this article, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or its Methodology Committee.

**Disclosures.** None of the individuals has any affiliations or financial involvement that conflict with the material presented in this manuscript.

## References

1. Sun F, Schoelles K (ECRI Institute). A systematic review of methods for health care technology horizon scanning. Rockville (MD): Agency for Healthcare Research and Quality; 2013. AHRQ Publication No. 13-EHC104-EF. Contract No. 290-2010-00006-C.
2. Palomino MA, Bardsley S, Bown K, De Lurio J, Ellwood P, Holland-Smith D, et al. Web-based horizon scanning: Concepts and practice. *Foresight*. 2012;14:355–73.
3. Hulshizer R, Lynch M, De Lurio J, Erinoff E, Robertson D, Tipton K, et al. (ECRI Institute) Horizon scanning protocol and operations manual. Washington (DC): Patient-Centered Outcomes Research Institute; revised 2020 Jun. Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12.
4. Agency for Healthcare Research and Quality (AHRQ) [Internet] About the effective health care program [cited 2020 Sep 8]; Available from: <https://effectivehealthcare.ahrq.gov/about>
5. Patient-Centered Outcomes Research Institute (PCORI) [Internet] Health care horizon scanning system [cited 2020 Sep 8]; Available from: <https://www.pcori.org/research-results/evidence-synthesis/pcori-health-care-horizon-scanning-system>
6. Hulshizer R, Carlson D, Cuevas C, Druga A, Lynch M, Mehta M, et al. (ECRI Institute). PCORI Health Care Horizon Scanning System: High Potential Disruption Report May 2020. Washington (DC): Patient-Centered Outcomes Research Institute; 2020. Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12.
7. Hulshizer R, Carlson D, Cuevas C, Druga A, Hudson K, Lynch M, et al. (ECRI Institute). PCORI Health Care Horizon Scanning System: Horizon Scanning Status Report December 2019. Washington (DC): Patient-Centered Outcomes Research Institute; 2019. Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12.
8. Patient-Centered Outcomes Research Institute (PCORI) [Internet] PCORI engagement rubric. Updated 2014 Feb 4 [cited 2020 Sep 8]; Available from: <https://www.pcori.org/sites/default/files/Engagement-Rubric.pdf>

9. **Hulshizer R, Carlson D, Cuevas C, Hudson K, Lynch M, Mehta M, et al.** (ECRI Institute). PCORI Health Care Horizon Scanning System: High Potential Disruption Report May 2019. Washington (DC): Patient-Centered Outcomes Research Institute; 2019. Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12.
10. **Hulshizer R, Carlson D, Cuevas C, Druga A, Hudson K, Lynch M, et al.** (ECRI Institute). PCORI Health Care Horizon Scanning System: High Potential Disruption Report November 2019. Washington (DC): Patient-Centered Outcomes Research Institute; 2019. Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12.
11. **Plain Language Action and Information Network (PLAIN)** [Internet]. Federal plain language guidelines. Updated 2011 Mar 1 [cited 2020 Sep 8]; Available from: <https://plainlanguage.gov/media/FederalPLGuidelines.pdf>
12. **Schrivier KA.** Plain language in the US gains momentum: 1940–2015. *IEEE Trans Prof Commun.* 2017;**60**:343–83.
13. **Abelson J, Wagner F, DeJean D, Boesveld S, Gauvin FP, Bean S, et al.** Public and patient involvement in health technology assessment: A framework for action. *Int J Technol Assess Health Care.* 2016;**32**:256–64.
14. **Scott AM, Wale JL.** Patient advocate perspectives on involvement in HTA: An international snapshot. *Res Involv Engagem.* 2017;**3**:2.
15. **Pomey MP, Brouillard P, Ganache I, Lambert L, Boothroyd L, Collette C, et al.** Co-construction of health technology assessment recommendations with patients: An example with cardiac defibrillator replacement. *Health Expect.* 2020;**23**:182–92.
16. **National Institute for Health Research (NIHR)** [Internet]. NIHR launches new Centre for Engagement and Dissemination. Updated 2020 Jan 4 [cited 2020 Sep 8]; Available from: <https://www.nihr.ac.uk/news/nihr-launches-new-centre-for-engagement-and-dissemination/24576>
17. **Institute for Clinical and Economic Review (ICER).** 2020–2023 Value assessment framework: Response to public comments. 2020.
18. **Berglas S, Jutai L, MacKean G, Weeks L.** Patients' perspectives can be integrated in health technology assessments: An exploratory analysis of CADTH common drug review. *Res Involv Engagem.* 2016;**2**:21.
19. **Staley K, Doherty C.** It's not evidence, it's insight: Bringing patients' perspectives into health technology appraisal at NICE. *Res Involv Engagem.* 2016;**2**:4.
20. **ECRI** [Internet]. Bulimia Nervosa Resource Guide [cited 2020 Sep 8]; Available from: <http://www.bulimiaguide.org>
21. **ECRI, American Association of Health Plans (AAHP).** Should I enter a clinical trial? A patient reference guide for adults with a serious or life threatening illness. A report by ECRI commissioned by AAHP; 2002.
22. **Simpson S, Cook A, Miles K.** Patient and public involvement in early awareness and alert activities: An example from the United Kingdom. *Int J Technol Assess Health Care.* 2018;**34**:10–7.
23. **Dykema J, Garbarski D, Wall IF, Edwards DF.** Measuring trust in medical researchers: Comparing agree-disagree and construct-specific survey questions. *J Off Stat.* 2019;**35**:353–86.
24. **Willits FK, Theodori GL, Luloff AE.** Another look at Likert scales. *J Rural Soc Sci.* 2016;**31**:126–39.
25. **Shulman HC, Dixon GN, Bullock OM, Colón Amill D.** The effects of jargon on processing fluency, self-perceptions, and scientific engagement. *J Lang Soc Psychol.* 2020: 1–19.